Clin Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leichter, S. B.
Right arrow Articles by Thomas, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Leichter, S. B.
Right arrow Articles by Thomas, S.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Clinical Diabetes 21:175-178, 2003
© American Diabetes Association ®, Inc., 2003

The Business of Diabetes

Combination Medications in Diabetes Care: An Opportunity That Merits More Attention

Steven B. Leichter, MD, FACP, FACE and Stephanie Thomas, CRC

The first 300 words of the full text of this article appear below.


   Introduction
 
During the past few years, new pills have been marketed that are combinations of two separate medications. At present, these products apply to three specific treatment areas related to diabetes: diabetes itself, lipidemia, and hypertension (Table 1). Until recently, the only combination pills on the market for these disease states were combinations of diuretics and one other blood pressure medication. In the past few years, a number of newer combination diabetes and lipid medications have been released, starting with metformin-glyburide, metformin-glipizide, metformin-rosiglitazone, and lovastatin-niacin. More combinations are planned.


View this table:
[in this window]
[in a new window]
  		Table 1. Newer Combination Products for the Treatment of Diabetes, Lipidemia, and Hypertension*

 
In all cases, these combination medications are mixtures of two existing drugs that have already been marketed. In all cases thus far, providers have had extensive opportunities to gain experience with both of the combined drugs as single agents, as well as moderate experience in combining them to treat more resistant cases. Clearly, a primary motive for developing and marketing the combination tablet has been economic—an effort by the manufacturer either to extend the patent life and profitability of the key agent in the combination because patent protection was about to expire or to create a new market for an agent that would perform better than the single-agent competition.

Although the economic motives for the introduction of combination products seem understandable, the benefits of these combination agents for patients and providers have not been explored in detail. One possibility, that these drugs improve patient adherence to treatment by eliminating one pill in the polypharmacy many patients face,1 has recently been challenged.2 A new study in the journal Diabetes Care suggests that, in contrast to other patient populations,3 diabetic patients do not have a reduction in adherence to their medical regimen when multiple medications are prescribed. If . . . [Full Text of this Article]


   Combination Drugs and Patient Adherence
 

   Adherence to oral medication regimens in diabetic patients
 

   Effects of combination medications on adherence
 

   Cost Advantages of Combination Medications
 

   Clinical Application of Combination Products
 

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Clin. DiabetesHome page
S. B. Leichter
Effects of the Medicare Modernization Act on Clinicians Involved in Diabetes Care
Clin. Diabetes, January 1, 2006; 24(1): 12 - 13.
[Full Text] [PDF]

Home page
 Clin. DiabetesHome page
S. B. Leichter
Making Outpatient Care of Diabetes More Efficient: Analyzing Noncompliance
Clin. Diabetes, October 1, 2005; 23(4): 187 - 190.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2003 by the American Diabetes Association.